IDXX Stock Overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
IDEXX Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$364.83|
|52 Week High||US$706.95|
|52 Week Low||US$330.66|
|1 Month Change||-27.16%|
|3 Month Change||-25.46%|
|1 Year Change||-32.34%|
|3 Year Change||43.88%|
|5 Year Change||117.94%|
|Change since IPO||38,493.61%|
Recent News & Updates
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|IDXX||US Medical Equipment||US Market|
Return vs Industry: IDXX underperformed the US Medical Equipment industry which returned -15.5% over the past year.
Return vs Market: IDXX underperformed the US Market which returned -11.5% over the past year.
|IDXX Average Weekly Movement||6.6%|
|Medical Equipment Industry Average Movement||10.6%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: IDXX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IDXX's weekly volatility (7%) has been stable over the past year.
About the Company
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
IDEXX Laboratories Fundamentals Summary
|IDXX fundamental statistics|
Is IDXX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDXX income statement (TTM)|
|Cost of Revenue||US$1.36b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 02, 2022
|Earnings per share (EPS)||8.74|
|Net Profit Margin||22.43%|
How did IDXX perform over the long term?See historical performance and comparison
Is IDEXX Laboratories undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IDXX ($364.83) is trading above our estimate of fair value ($312.62)
Significantly Below Fair Value: IDXX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDXX is poor value based on its PE Ratio (41.7x) compared to the US Medical Equipment industry average (34.4x).
PE vs Market: IDXX is poor value based on its PE Ratio (41.7x) compared to the US market (15.5x).
Price to Earnings Growth Ratio
PEG Ratio: IDXX is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: IDXX is overvalued based on its PB Ratio (47.9x) compared to the US Medical Equipment industry average (2.4x).
How is IDEXX Laboratories forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDXX's forecast earnings growth (13.5% per year) is above the savings rate (1.9%).
Earnings vs Market: IDXX's earnings (13.5% per year) are forecast to grow faster than the US market (12.4% per year).
High Growth Earnings: IDXX's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDXX's revenue (10% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: IDXX's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDXX's Return on Equity is forecast to be very high in 3 years time (66%).
How has IDEXX Laboratories performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDXX has high quality earnings.
Growing Profit Margin: IDXX's current net profit margins (22.4%) are lower than last year (23.6%).
Past Earnings Growth Analysis
Earnings Trend: IDXX's earnings have grown significantly by 23.9% per year over the past 5 years.
Accelerating Growth: IDXX's earnings growth over the past year (9%) is below its 5-year average (23.9% per year).
Earnings vs Industry: IDXX earnings growth over the past year (9%) underperformed the Medical Equipment industry 16.1%.
Return on Equity
High ROE: Whilst IDXX's Return on Equity (114.8%) is outstanding, this metric is skewed due to their high level of debt.
How is IDEXX Laboratories's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: IDXX's short term assets ($1.1B) exceed its short term liabilities ($971.3M).
Long Term Liabilities: IDXX's short term assets ($1.1B) exceed its long term liabilities ($981.6M).
Debt to Equity History and Analysis
Debt Level: IDXX's net debt to equity ratio (151.4%) is considered high.
Reducing Debt: IDXX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IDXX's debt is well covered by operating cash flow (63.6%).
Interest Coverage: IDXX's interest payments on its debt are well covered by EBIT (32.5x coverage).
What is IDEXX Laboratories's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDXX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDXX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IDXX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Mazelsky (60 yo)
Mr. Jonathan J. Mazelsky, also known as Jay, has been President, Chief Executive Officer and Director at IDEXX Laboratories, Inc. since October 23, 2019. Mr. Mazelsky was an Interim President and Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD9.07M) is below average for companies of similar size in the US market ($USD13.26M).
Compensation vs Earnings: Jay's compensation has increased by more than 20% in the past year.
Experienced Management: IDXX's management team is considered experienced (2.3 years average tenure).
Experienced Board: IDXX's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
IDEXX Laboratories, Inc.'s employee growth, exchange listings and data sources
- Name: IDEXX Laboratories, Inc.
- Ticker: IDXX
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$30.018b
- Shares outstanding: 84.01m
- Website: https://www.idexx.com
Number of Employees
- IDEXX Laboratories, Inc.
- One IDEXX Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.